MedTrace Logo

Effects of the Postbiotic Blend ABB C3 on Adiposity and Glucose Metabolism in Children and Adolescents

NCT06309121 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-03-23

No results posted yet for this study

Summary

This study investigates the effects of a postbiotic combination called ABB C3 on reducing body fat and improving metabolic health in children and teenagers. The study consists of a 3-month trial with half participants taking ABB C3 and the other half a placebo, monitoring body composition and blood markers. Afterward, participants can continue with ABB C3 for an additional 3 months. The goal is to determine if ABB C3 is a safe and effective way to help young people improve their health by reducing body fat.

Conditions

  • Obesity, Childhood
  • Obesity, Adolescent

Interventions

DIETARY_SUPPLEMENT

Postbiotic ABB C3

A daily dose of 550 mg of the postbiotic blend ABB C3 in individual sachets for the first 3 months of the study.

DIETARY_SUPPLEMENT

Placebo

A daily dose of 550 mg of the placebo in individual sachets for the first 3 months of the study.

DIETARY_SUPPLEMENT

Follow-up Postbiotic ABB C3 (Optional)

Option given to all participants: a daily dose of 550 mg of the postbiotic blend ABB C3 in individual sachets for months 4 to 6 of the study.

Sponsors & Collaborators

  • Fundació Sant Joan de Déu

    lead OTHER

Principal Investigators

  • Carles Lerin, PhD · Fundació Sant Joan de Deu

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-10
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06309121 on ClinicalTrials.gov